BioSante Pharmaceuticals VP of Clinical Development To Present at The Endocrine Society’s 90th Annual Meeting
Sunday, June 15, 2008, at the Moscone Center in San Francisco, Calif.
Lincolnshire, Illinois (June 12, 2008) – Michael C. Snabes, MD, PhD, vice president of clinical development of BioSante Pharmaceuticals (NASDAQ: BPAX), will be presenting an overview of a key study in the LibiGel® (testosterone gel) development program at The Endocrine Society’s 90th Annual Meeting in San Francisco at the Moscone Center on Sunday, June 15, 2008. The Endocrine Society’s Annual Meeting (ENDO) is a leading venue for physicians and other clinicians who treat endocrine conditions, including female sexual dysfunction.
Dr. Snabes will be presenting a poster entitled, “A Cardiovascular and Breast Safety Study of LibiGel® in Women with Hypoactive Sexual Desire Disorder (HSDD): Study Design and Description of Endpoints.” The poster is one of the few presentations and abstracts identified by The Endocrine Society as “being particularly newsworthy.” A report of these abstracts, and corresponding lay translations for the media, serves as a vital resource for attending journalists during the meeting and a lasting reference guide for reporters. A news conference will be held on Sunday, June 15, 2008, at which time reporters will be invited to view the poster and discuss LibiGel® and the described study with Dr. Snabes.
“It is a privilege to be representing BioSante at such a prestigious event as ENDO, and we are grateful to The Endocrine Society for extending this invitation to us,” said Dr. Snabes. “The Endocrine Society has called for more long-term safety data on testosterone in the treatment of HSDD. BioSante is answering this call by sponsoring this Phase III cardiovascular safety study to show the safety of LibiGel® in menopausal women.”
About The Endocrine Society
The Endocrine Society delivers an unparalleled forum for cross-discipline collaboration with more than 14,000 members in over 90 countries. The Society hosts two annual meetings, ENDO™ and the Clinical Endocrinology Update, and offers ACCME and AMA- compliant CME opportunities. Endocrine research is supported through effective public advocacy and we issue $1.5 million in awards annually. In addition, the Society publishes four prestigious, peer-reviewed journals, as well as Endocrine News, the monthly endocrine magazine that delivers the latest clinical trends and research updates. The Society’s Clinical Practice Guidelines on endocrine disorders are vetted through a rigorous multi-step review process and promotes the standards of excellence embraced by the Society. The Society also has a public education affiliate, The Hormone Foundation, which provides patient materials on a variety of endocrine disorders. These materials are available online at www.hormone.org . To learn more, visit www.endo-society.org
During the course of ENDO, over 200 scientific sessions are produced in a variety of formats on topics covering the full range of endocrinology from basic and translational research to clinical practice. The ENDO 08 scientific program includes 16 Plenary Sessions, 160 Meet-the-Professor sessions, over 76 symposia, and 350 speakers representing the world’s best endocrinologists.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.